ArticleMolecular cancer therapeutics2015

Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.

Salvatore Lopez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.